auranofin, Ridaura

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Pharmacy Author: Annette (Gbemudu) Ogbru, PharmD, MBA
    Annette (Gbemudu) Ogbru, PharmD, MBA

    Dr. Gbemudu received her B.S. in Biochemistry from Nova Southeastern University, her PharmD degree from University of Maryland, and MBA degree from University of Baltimore. She completed a one year post-doctoral fellowship with Rutgers University and Bristol Myers Squibb.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

Get a Grip on Rheumatoid Arthritis

An itching sensation can be an early warning sign of a skin reaction, such as a rash. Auranofin also can cause a metallic taste and mouth sores, though less frequently than injectable gold salts. Because gold salts can cause serious kidney and bone marrow problems, all patients require monitoring with regular testing of blood and urine. Hair loss, anemia, and reduced number of white blood cells or platelets have also been reported.

PRESCRIPTION: Yes

GENERIC AVAILABLE: No

PREPARATIONS: Capsule: 3 mg.

STORAGE: Auranofin should be stored between 15 C and 30 C (59 F and 86 F) and dispensed in a tight, light-resistant container

DOSING: The usual adult dosage of auranofin is 3 mg twice daily or 6 mg once a day. The dose may be increased to 3 mg three times daily after three months.

DRUG INTERACTIONS: The concurrent use of auranofin and phenytoin (Dilantin), an antiepileptic drug, may increase phenytoin blood levels, which may lead to phenytoin toxicity for unclear reasons. The concurrent use of penicillamine (Cuprimine, Depen) and gold salts may result in blood cell or kidney toxicity since both drugs are toxic to the blood cells and kidney. The auranofin should not be used with atovaquone/proguanil (Malarone) an antimalarial drug, as the combination may increase the risk of toxicity to blood cells.

PREGNANCY: There are no adequate studies in pregnant women. Use of auranofin in pregnant women is not recommended.

NURSING MOTHERS: Auranofin has been found in the breast milk of nursing mothers. Nursing during auranofin therapy is not recommended.

Medically reviewed by Eni Williams, PharmD

Reference: FDA Prescribing Information

Medically Reviewed by a Doctor on 6/16/2015

Quick GuideRheumatoid Arthritis (RA) Pictures Slideshow

Rheumatoid Arthritis (RA) Pictures Slideshow
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Arthritis Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors